Cargando…

Future of bisphosphonates and denosumab for men with advanced prostate cancer

Prostate cancer is the most common cancer occurring in American men of all races. It is also the second leading cause of cancer death among men in the USA. Bone metastasis is a frequent occurrence in men with advanced prostate cancer, with skeletal-related events being a common complication and havi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iranikhah, Maryam, Stricker, Steve, Freeman, Maisha Kelly
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014380/ https://www.ncbi.nlm.nih.gov/pubmed/24833918 http://dx.doi.org/10.2147/CMAR.S40151

Ejemplares similares

Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion
por: Body, Jean-Jacques, et al.
Publicado: (2018)

Can denosumab be a substitute, competitor, or complement to bisphosphonates?
por: Kim, Su Young, et al.
Publicado: (2017)

A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives
por: Chatziravdeli, Vasiliki, et al.
Publicado: (2022)

Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis
por: Benjamin, Biju, et al.
Publicado: (2016)

The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review
por: Inojosa, Arthur Costa, et al.
Publicado: (2022)

Denosumab Reduces the Incidence of New Vertebral Fractures in Men With Prostate Cancer
por: Silver, David S.
Publicado: (2010)

Osteoporosis in men: epidemiology and treatment with denosumab
por: Sidlauskas, Kristel M, et al.
Publicado: (2014)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
por: Zhu, Yilin, et al.
Publicado: (2019)

Comparing the Efficacy and Safety of Denosumab with Bisphosphonates in Increasing Bone Mineral Density in Patients with Prostate Cancer and Breast Cancer on Antihormonal Treatment
por: Razaq, Abdul, et al.
Publicado: (2019)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
por: Wu, Jiaqi, et al.
Publicado: (2018)

Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention?
por: Sydlik, Carmen, et al.
Publicado: (2020)

Denosumab-Induced Rebound Hypercalcemia Treated With Bisphosphonates in a Pediatric Patient
por: Gandolfi, Anne, et al.
Publicado: (2023)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Denosumab: Delay of bone metastasis in men with nonmetastatic castrate-resistant prostate cancer
por: Manger, Jules P., et al.
Publicado: (2012)

Use of bisphosphonates in advanced prostate cancer: Current status
por: Lilleby, Wolfgang
Publicado: (2007)

Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment
por: Hu, Mimi I., et al.
Publicado: (2013)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
por: Zanchetta, Maria Belen, et al.
Publicado: (2019)

MON-335 Bisphosphonate and Denosumab Refractory Hypercalcemia of Malignancy: What Else Is at Play?
por: Patel, Reshma, et al.
Publicado: (2020)

Persistence with oral bisphosphonates and denosumab among older adults in primary care in Ireland
por: Walsh, Mary E., et al.
Publicado: (2021)

Bisphosphonates Versus Denosumab for Prevention of Pathological Fracture in Advanced Cancers With Bone Metastasis: A Meta-analysis of Randomized Controlled Trials
por: Al Farii, Humaid, et al.
Publicado: (2020)

The role of bisphosphonates in breast cancer: The present and future role of bisphosphonates in the management of patients with breast cancer
por: Brown, Janet E, et al.
Publicado: (2002)

Management of bone metastases in refractory prostate cancer – role of denosumab
por: Paller, Channing J, et al.
Publicado: (2012)

Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany
por: Diel, Ingo, et al.
Publicado: (2020)

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2020)

Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
por: Shimizu, Tomohiro, et al.
Publicado: (2021)

Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study
por: Marocco, Chiara, et al.
Publicado: (2021)

Association of Antiosteoporotic Medication Bisphosphonates and Denosumab with Primary Breast Cancer: An Electronic Health Record Cohort Study
por: Stanoyevitch, Alexander, et al.
Publicado: (2021)

Clinical utility of denosumab for treatment of bone loss in men and women
por: Adler, Robert A, et al.
Publicado: (2011)

Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
por: Petranova, T., et al.
Publicado: (2017)

Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women
por: Augoulea, A., et al.
Publicado: (2017)

Atypical Femoral Fracture in a Patient without Bisphosphonate or Denosumab Exposure-A Case Report
por: Georgiadis, George F., et al.
Publicado: (2021)

The role of bisphosphonates in breast cancer: Development of bisphosphonates
por: Fleisch, Herbert
Publicado: (2002)

Denosumab, an effective osteoporosis treatment option for men
por: Kong, Sung Hye
Publicado: (2022)

Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
por: Kamimura, M., et al.
Publicado: (2016)

GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab
por: Hadji, P., et al.
Publicado: (2016)

The effect of previous treatment with bisphosphonate and renal impairment on the response to denosumab in osteoporosis: a ‘real-life’ study
por: Fraser, T. R., et al.
Publicado: (2019)

Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
por: Jiang, Lianghai, et al.
Publicado: (2022)

Single Dose of Denosumab Effective for Management of Bisphosphonate-Refractory Hypercalcemia of Malignancy Related to Non-Small Cell Lung Cancer
por: Dinh, Kathryn, et al.
Publicado: (2021)

Severe Hypocalcemia due to Denosumab in Metastatic Prostate Cancer
por: Muqeet Adnan, Mohammed, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vbfr2icqlsi4e1kkhioeipotiu